Defining Value Among Treatment Options
Payer decision-makers discuss defining value among agents for unintended pregnancy, uterine fibroids, and endometriosis.
Evolving Treatment Strategies for UF and Endometriosis
A panel of experts discuss treatment selection among contraceptive agents and evolving treatment strategies for uterine fibroids and endometriosis.
Economic Burden of Unintended Pregnancy
Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.
Identifying Risk Factors For UF and Endometriosis
Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.
Drivers of Healthcare Utilization in Women’s Health
Kevin Stephens, Sr. MD, JD examines key drivers of healthcare utilization for women of childbearing years.
A Paradigm Shift in Treatment of UF and Endometriosis
Steven McCarus, MD FACOG highlights the shift away from surgical treatment toward medical therapy in UF and endometriosis.
Payer Considerations in Women’s Reproductive Health
Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.
Common Conditions During Reproductive Years
Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.
CVD Risk in Prostate Cancer: Future Directions in Care
Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.
Multidisciplinary Care in Prostate Cancer and CVD Management
Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.
CVD Risk in Prostate Cancer: Quality Measures and Coverage Policy
Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.
What Evidence Is Needed to Further Define CVD Risk in Prostate Cancer?
Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.
Factors in Evaluating Therapy for Prostate Cancer
Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.
Key Takeaways on Optimizing Glaucoma Management
Closing out their discussion on glaucoma management, experts share practical advice for care providers and payers alike.
CVD in Prostate Cancer: Risk-Bearing Practices and Alternative Payment Models
Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.
Impact of CVD Risk on Cost of Care in Prostate Cancer
Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.
How Will the Glaucoma Treatment Landscape Evolve in Coming Years?
Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years.
Glaucoma: Considering MIGS and Other Channel Procedures
Expert panelists review the use of MIGS and other channel procedures in patients with glaucoma.
Prostate Cancer and CVD: Professional Society Guidelines
Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.
Prostate Cancer: Identifying Patients at Risk for CVD
A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.
Selective Laser Trabeculoplasty Use in Glaucoma
A review of selective laser trabeculoplasty in glaucoma management, and when it is appropriate to consider as a treatment option.
Novel Therapy in Glaucoma: Sustained Delivery Implants
A review of the novel sustained release approach with bimatoprost implants and how this is affecting glaucoma management.
CVD Risk Associated With ADT in Prostate Cancer
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.
An Overview of the Prostate Cancer Treatment Landscape
A comprehensive review of the therapeutic classes available for patients with prostate cancer.
Use of Rho Kinase Inhibitors in Glaucoma
Panelists discuss the role of rho kinase inhibitors in glaucoma management respective to cost, efficacy, and ease of use.
Addressing Patient Adherence in Glaucoma Management
Shared insight on the importance of patient adherence in glaucoma management, and how this is influenced by therapeutic regimens.
Correlation Between Prostate Cancer and Cardiovascular Disease
Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.
Prostate Cancer’s Impact on Economy and Life
A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.
Factors Guiding Selection of Therapy for Glaucoma
Expert perspectives on the factors that inform therapy selection when managing patients with glaucoma.
Considering Generic Vs Branded Therapy for Glaucoma
Experts debate the use of generic agents over branded therapy when managing patients with glaucoma.
2 Clarke Drive Cranbury, NJ 08512